Biovica International AB (publ) announces that a observational trial with DiviTum TKa has started at Mayo Clinic in Florida. If successful, it will further validate the utility of DiviTum TKa as an effective tool for disease monitoring. The study is conducted in 100 patients with hormone receptor-positive (HR+) metastatic breast cancer undergoing standard of care therapies ?

either CDK4/6 inhibitors combined with endocrine therapy (ET) or ET monotherapy ? over a period of two years, providing up to 27 serial samples per patient throughout the study. By conducting real-time serial measurements of thymidine kinase activity (TKa) in conjunction with patient characteristics, tumor features, disease stability, pharmacokinetics, and patient outcomes, the study aims to refine and enhance the precision of treatment approaches.